Caribou Biosciences Halts CAR-T Pipeline and Cuts Staff Amid Funding Freeze

Key points

• Caribou Biosciences announced on Oct. 6 that it is halting all clinical development and implementing substantial workforce reductions, expected to be complete by Q4 2026.
• The company is exploring strategic alternatives, including a merger, acquisition, or sale of assets, after failing to raise funds for a pivotal Phase 3 trial of its lead candidate, vispa-cel.
• CEO Rachel Haurwitz stated that the decision stems from a difficult financing environment for allogeneic CAR-T therapies, not a lack of belief in the science, noting that the company had $113.8 million in cash as of June 30.
• Shares of Caribou dropped approximately 35% to 43% in early trading following the news, with RBC cutting its price target by 90%.
• The company’s two main programs, vispa-cel for lymphoma and CB-011 for multiple myeloma, had shown promising Phase 1 results, including an 82% overall response rate for vispa-cel, but could not secure further funding.

Background

Caribou Biosciences, spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, focused on allogeneic (donor-derived) CAR-T therapies to avoid the lengthy manufacturing times of patient-specific treatments. The company had previously secured funding from major pharma firms like Novartis, AbbVie, and Pfizer, and went public in 2021. However, the broader biotech landscape has shifted toward in vivo gene editing and autologous therapies, creating a funding 'nuclear winter' for off-the-shelf cell therapy developers. Other competitors, such as Cellectis, have also pivoted away from allogeneic approaches due to similar financing challenges.

How outlets are covering it

Fierce Biotech and BioSpace emphasize the 'heartbreaking' nature of the decision and the specific financial constraints, noting that Caribou had sufficient cash to fund early-stage activities but could not secure the capital for a pivotal trial. STAT highlights the failure to raise money for the late-stage trial as the primary driver for the shutdown. Yahoo Finance focuses on the market reaction, reporting a 35% premarket stock crash and a 90% cut in the RBC price target. All sources agree that the decision is driven by the current financing environment for allogeneic CAR-T therapies, which has become increasingly difficult due to investor preference for in vivo and autologous methods.

Why it matters

The shutdown of Caribou Biosciences signals a significant shift in the cell therapy landscape, where funding is increasingly favoring in vivo and autologous approaches over allogeneic (off-the-shelf) therapies. This move may impact the future of donor-derived cell therapies and could lead to the acquisition of Caribou’s promising assets by larger pharmaceutical companies with greater resources.

What to watch

Caribou Biosciences will continue to seek strategic alternatives, including a merger, acquisition, or sale of its assets, particularly its lead candidate vispa-cel, which had agreed with the FDA on the design of a pivotal Phase 3 trial. The company expects to complete its workforce reductions by the end of 2026 and will incur $15 million to $19 million in restructuring costs.